CAMBRIDGE, Mass., June 18, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of.

CAMBRIDGE, Mass., Nov. 15, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies.

CAMBRIDGE, Mass., May 11, 2020 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of.

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) ...

After a thorough analysis of the data, Anchiano determined that there is a low probability of surpassing the pre-defined futility threshold at the planned interim analysis, which required 10 complete responses in 35 patients. The data also indicate a low probability of achieving an efficacy profile that in the company’s estimation would be necessary to support regulatory approval.

Entered into an exclusive worldwide collaboration and option to license agreement on September 20, 2019 with ADT Pharmaceuticals, LLC (“ADT”) to develop novel small-molecule pan-RAS inhibitors and PDE10/β-catenin inhibitors aimed at difficult-to-treat, genetically-defined cancers, underscoring Anchiano’s focus on developing therapies with targeted approaches. Anchiano believes that successful development of its pan-RAS-targeted therapy, with activity regardless of RAS isoform or mutation, has the potential for significant clinical impact across a variety of tumor types including lung, colorectal, pancreatic, melanoma and bladder cancer, and represents a substantial commercial opportunity.

Anchiano Therapeutics Ltd. (ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today announced Stephen Hoffman, M.D., Ph.D. is stepping down from the Board of Directors effective immediately. “Steve led the company through the initiation of its pivotal clinical trial Codex, to its public offering and Nasdaq listing, and the recent acquisition of its RAS-inhibitor program,” said Frank Haluska M.D., Ph.D., President and Chief Executive Officer of Anchiano.

Anchiano Therapeutics Ltd. (ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today reported that Anchiano Therapeutics, Inc., the Company’s U.S. subsidiary, has entered into an exclusive worldwide collaboration and option to license agreement with ADT Pharmaceuticals, LLC (“ADT”) to develop novel small-molecule inhibitors of RAS and PDE10/β-catenin. This collaboration reflects Anchiano’s ongoing strategy to grow a pipeline beyond its pivotal-stage asset, inodiftagene vixteplasmid, with programs that have the potential to address significant clinical needs, while leveraging Anchiano’s expertise in small-molecule oncology development.

Anchiano Therapeutics Ltd. (ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchiano by agreement with Danforth Advisors since 2018; he will succeed Jonathan Burgin, who is leaving the Company as part of the planned closure of the Company’s Israel offices and facilities.

CAMBRIDGE, Mass., Sept. 20, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development.

Anchiano Therapeutics Ltd. (ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on or about March 23, 2020. The matters raised by Access Industries Holdings LLC and Clal Biotechnology Industries Ltd. will be addressed at the Annual Meeting. Holders of the Company’s ordinary shares and holders of the Company’s American Depositary Shares at the close of business on February 17, 2020, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting.

CAMBRIDGE, Mass., Aug. 05, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of.

CAMBRIDGE, Mass., Sept. 03, 2019 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development.

Anchiano Therapeutics Ltd. (ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) as a virtual meeting due to the ongoing public health concerns related to the coronavirus (COVID-19) pandemic. As described in the proxy materials for the Annual Meeting (the “Proxy Materials”), shareholders as of the close of business on March 23, 2020, the record date, are entitled to participate in the Annual Meeting. Shareholders can participate in the Annual Meeting via the internet by visiting https://anchiano.webex.com/anchiano/j.php?MTID=m99b0b42faed9b725d14a1b66c65252b7 and entering the meeting number (280 326 067).

Anchiano Therapeutics Ltd. (ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the board of Anchiano in April 2020. “We warmly welcome Stan as our new Chairman,” said Frank G. Haluska, M.D., Ph.D., President and Chief Executive Officer of Anchiano.